neuroendocrine tumors

Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis
Fierce Biotech
Thu, 09/12/24 - 11:35 am
Sanofi
radioligands
neuroendocrine tumors
RadioMedix
Orano Med
AlphaMedix
Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors
Fierce Pharma
Fri, 01/19/24 - 11:19 am
Novartis
Lutathera
radiopharmaceuticals
neuroendocrine tumors
Novartis eyes first-line use of Lutathera after trial win
Pharmaphorum
Mon, 09/25/23 - 11:41 am
Novartis
radioligands
clinical trials
neuroendocrine tumors
Lutathera
Cabometyx study ends early after researchers see 'dramatic' benefits in neuroendocrine tumors, Exelixis says
Fierce Pharma
Thu, 08/24/23 - 08:37 pm
Carbometyx
Exelixis
clinical trials
neuroendocrine tumors
Chi-Med Halts Phase III Study Early After Meeting Primary Endpoint
BioSpace
Fri, 06/14/19 - 06:20 pm
Chi-Med
neuroendocrine tumors
clinical trials
surufatinib
Bristol-Myers Squibb's Opdivo-Yervoy duo provokes response in rare tumors
Fierce Pharma
Sun, 03/31/19 - 03:51 pm
Bristol-Myers Squibb
Opdivo
Yervoy
neuroendocrine tumors
As Novartis' other cancer launches struggle, Lutathera gets off to flying start
Fierce Pharma
Fri, 11/9/18 - 11:43 am
Novartis
Lutathera
drug launches
neuroendocrine tumors
Esanex Has Successful Ph II Meeting with FDA Meeting for SNX-5422 Upcoming Trial in Neuroendocrine Tumors
CP Wire
Thu, 10/4/18 - 09:44 am
Esanex Inc
SNX-5422
neuroendocrine tumors
Esanex Has Successful Ph II Meeting with FDA Meeting for SNX-5422 Upcoming Trial in Neuroendocrine Tumors
Thu, 10/4/18 - 09:28 am
Esanex Inc
SNX-5422
neuroendocrine tumors
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Endpoints
Fri, 01/26/18 - 05:25 pm
Novartis
Lutathera
FDA
neuroendocrine tumors
Progenics Azedra Succeeds in Mid-Stage Trials
Investopedia
Fri, 03/31/17 - 09:50 am
Progenics
Azedra
clinical trials
neuroendocrine tumors
OncoMed Pharmaceuticals Presents Updated Phase 1a Data in Advanced Solid Tumor Patients for the First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) at the European Cancer Congress 2013
Yahoo/GlobeNewsWire
Sun, 09/29/13 - 01:32 pm
vantictumab
OMP-18R5
neuroendocrine tumors
OncoMed
solid tumors
Inspire Launches Online Community to Connect Patients Affected by Pancreatic Neuroendocrine Tumors (PNET)
CP Wire
Fri, 07/12/13 - 09:25 am
neuroendocrine tumors
social media
Inspire
Sutent Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Yahoo/BusinessWire
Sat, 05/21/11 - 11:11 am
Sutent
neuroendocrine tumors
Pfizer
Novartis Adds New Drug Approvals In May
Investor's Business Daily
Sat, 05/21/11 - 11:10 am
Novartis
Afinitor
neuroendocrine tumors